09.02.2025
Alivexis, Inc. (CEO: Roy S. Kimura, COO: Kazuki Ohno; Headquarters: Tokyo, Japan; formerly known as Modulus Discovery, Inc.) has received notice that Astellas Pharma Inc. will exercise its option to license a novel small molecule compound identified through their joint drug discovery collaboration.
The small molecule compounds were discovered using Alivexis’s proprietary ModBind™ computational platform for a novel target selected by Astellas. The collaboration aims to accelerate the identification of small molecule therapeutics through a fully integrated approach combining in silico drug discovery with experimental validation.
As part of the collaboration, Alivexis led discovery effortsand assay development. The compound subject to this option exercise represents a significant milestone in the partnership, demonstrating the potential of Alivexis’s platform to rapidly generate drug candidates to novel targets.
Alivexis’s approach to computational drug discovery contributes to improving the efficiency and success rate of early-stage therapeutic development.
About Alivexis
Founded in August 2016, Alivexis, Inc. is a technology-driven drug discovery enterprise with operational foundations in both Japan and the US. By merging state-of-the-art drug discovery platforms with profound knowledge of disease biology and a dynamic global business approach, the company is propelling forward its distinct portfolio of small molecule drugs along with a variety of research and development collaborations. At present, Alivexis is dedicated to swiftly bringing innovative medications to individuals and their families grappling with cancer, both chronic and acute immune-inflammatory conditions, and rare diseases. For more information, visit https://alivexis.com.
About Fast Track Initiative:
Established in 2004, Fast Track Initiative, Inc. (FTI) is a life science venture capital firm focusing its investments on early-stage startups with a strong focus on biotech and therapeutics. FTI has a strict mission to make a ground-breaking impact on the quality of our life and human wellness through investments across a broad range of areas in the life science community including therapeutics, diagnostics, digital health, healthcare services, and more. The company provides valuable, hands-on support to its 30+ portfolio companies through business and R&D strategy, partnering, investor syndication, and more, including access to its network of professionals in Japan.
Visit https://us.fasttrackinitiative.com for more details, or follow us on LinkedIn: https://www.linkedin.com/company/fast-track-initiative/
Media Contact:
For press inquiries or investor inquiries, please email: message.us@fasttrackinitiative.com
